Inflammatory Bowel Diseases
Conditions
Keywords
Inflammatory Bowel Disease
Brief summary
Pathologically Inflammatory bowel disease (IBD) is in chronic complex inflammatory gut pathological condition. Although the etiology of IBD is unknown, gut microbiota alteration (dysbiosis) is considered a novel factor involved in the pathogenesis of IBD. The aim of this study is to analyze gut microbiota in IBD patients.
Detailed description
Inflammatory bowel disease (IBD) (Crohn's disease (CD) and ulcerative colitis (UC)) occurs worldwide with differences in epidemiology, etiology, and phenotype between regions. Pathologically Inflammatory bowel disease (IBD) is in chronic complex inflammatory gut pathological condition. Although the etiology of IBD is unknown, gut microbiota alteration (dysbiosis) is considered a novel factor involved in the pathogenesis of IBD. The DNA of microbiota will be investigated with samples of stool, colon tissue. The aim is to establish a cohort group for IBD (1), to make a database on cohort group characteristics such as endoscopic findings, disease severity, epidemiology, and prognosis (2), to analyze gut flora in IBD patients (3).
Interventions
None listed
Sponsors
Yeouido St. Mary's Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 75 Years
Healthy volunteers
No
Inclusion criteria
* The below 3 conditions must be met simultaneously. 1. Patient who can voluntarily consent to this study. 2. Patient who has inflammatory bowel disease. 3. Patient who is aged less than 75 years.
Exclusion criteria
* a patient meets any of the below conditions. 1. If a patient has an IBD other than UC and CD. 2. If a patient is vulnerable due to his/her position as an employee of Yeouido St.Mary's hospital or a medical student of the Catholic University of Korea. 3. If a patient is pregnant. 4. Foreign personal who cannot speak Korean.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with the remission of disease activity. | through study completion, an average of 2 year | Disease activity is assessed in a clinical, endoscopic, and biochemical way. Each activity is determined by the Mayo score (in UC), Crohn's Disease Activity Index (in CD), Ulcerative Colitis Endoscopic Index of Severity (in UC), Simple Endoscopic Score for Crohn Disease (in CD), and biochemical findings (e.g. fecal calprotectin). |
Countries
South Korea
Outcome results
None listed